0000899243-22-027157.txt : 20220801
0000899243-22-027157.hdr.sgml : 20220801
20220801161528
ACCESSION NUMBER: 0000899243-22-027157
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220801
FILED AS OF DATE: 20220801
DATE AS OF CHANGE: 20220801
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DEBBANE RAYMOND
CENTRAL INDEX KEY: 0001053890
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30111
FILM NUMBER: 221124916
MAIL ADDRESS:
STREET 1: C/O THE INVUS GROUP, LLC
STREET 2: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Invus US Partners LLC
CENTRAL INDEX KEY: 0001839806
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30111
FILM NUMBER: 221124919
BUSINESS ADDRESS:
STREET 1: 750 LEXINGTON AVE
STREET 2: 30TH FL
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-371-1717
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVE
STREET 2: 30TH FL
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER NAME:
FORMER CONFORMED NAME: Invus US Partners, LLC
DATE OF NAME CHANGE: 20210210
FORMER NAME:
FORMER CONFORMED NAME: Invus Partners, LLC
DATE OF NAME CHANGE: 20210108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ulys, L.L.C.
CENTRAL INDEX KEY: 0001340098
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30111
FILM NUMBER: 221124918
BUSINESS ADDRESS:
STREET 1: C/O THE INVUS GROUP, LLC
STREET 2: 750 LEXINGTON AVENUE, 30TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 212-317-1717
MAIL ADDRESS:
STREET 1: C/O THE INVUS GROUP, LLC
STREET 2: 750 LEXINGTON AVENUE, 30TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER NAME:
FORMER CONFORMED NAME: Ulys, LLC
DATE OF NAME CHANGE: 20050928
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001062822
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 760474169
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2445 TECHNOLOGY FOREST BLVD.
STREET 2: SUITE 1100
CITY: THE WOODLANDS
STATE: TX
ZIP: 77381
BUSINESS PHONE: 2818633000
MAIL ADDRESS:
STREET 1: 2445 TECHNOLOGY FOREST BLVD.
STREET 2: SUITE 1100
CITY: THE WOODLANDS
STATE: TX
ZIP: 77381
FORMER COMPANY:
FORMER CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE
DATE OF NAME CHANGE: 20070426
FORMER COMPANY:
FORMER CONFORMED NAME: LEXICON GENETICS INC/TX
DATE OF NAME CHANGE: 20000126
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-01
0
0001062822
LEXICON PHARMACEUTICALS, INC.
LXRX
0001839806
Invus US Partners LLC
C/O THE INVUS GROUP, LLC
750 LEXINGTON AVENUE 30TH FLOOR
NEW YORK
NY
10022
1
0
1
0
0001340098
Ulys, L.L.C.
750 LEXINGTON AVENUE, 30TH FLOOR
NEW YORK
NY
10022
1
0
1
0
0001053890
DEBBANE RAYMOND
C/O ULYS, L.L.C.
750 LEXINGTON AVENUE, 30TH FLOOR
NEW YORK
NY
10022
1
0
1
0
Common Stock
2022-08-01
4
P
0
982600
2.50
A
5303814
I
See Footnotes
Common Stock
331545
D
On July 27, 2022, Invus US Partners LLC entered into a purchase agreement with the Issuer pursuant to which Invus US Partners LLC agreed to purchase 982,600 shares of common stock, $0.001 par value per share (the "Issuer Common Stock") of the Issuer at a price of $2.50 per share. The purchase closed on August 1, 2022.
These securities are directly held by Invus US Partners LLC
These securities are directly held by Mr. Raymond Debbane.
Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C.
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Artal International S.C.A. directly holds 48,433,261 shares of Issuer Common Stock; Invus, L.P. directly holds 35,402,689 shares of Issuer Common Stock; and Invus Public Equities, L.P. directly holds 3,516,214 shares of Issuer Common Stock, which securities are being reported on a separately filed Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.
Invus US Partners LLC, By: /s/ Philip Bafundo , Name: Philip Bafundo, Title: Authorized Person
2022-08-01
ULYS, L.L.C., By: /s/ Raymond Debbane, Name: Raymond Debbane, Title: President
2022-08-01
RAYMOND DEBBANE, /s/ Raymond Debbane
2022-08-01